Fazal Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fazal Khan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Arosh Shavinda Perera Molligoda Arachchige
University of Milan, Milan, Italy, Italy
2 shared publications - Gabriel Amorim Moreira Alves
Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy
2 shared publications - Mohan Dodeja
Faculty of Medicine and Surgery Humanitas University Pieve Emanuele Italy
2 shared publications Rajendranandini Majumdar
Humanitas University, Lombardy, Italy
2 shared publicationsAmr Harby
Humanitas University, Lombardy, Italy
1 shared publicationAna Claudia Teixeira de Castro Gonçalves Ortega
Faculty of Medicine and Surgery Humanitas University Pieve Emanuele Italy
1 shared publication
Latest Publications
- 3 September 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 209
Prevalence of Claudin 18.2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Systematic Review and Meta-Analysis
- 3 September 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 209
Prevalence of Claudin 18.2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Systematic Review and Meta-Analysis
- Open Access
- 24 March 2026
- Published by Wiley in Chronic Diseases and Translational Medicine
- Vol. 12 (2) , 85-99
GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes
Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects over 30% of adults worldwide and represents a systemic cardiometabolic disorder in which cardiovascular disease is the leading cause of death. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are uniquely positioned to address this liver–heart axis by combining hepatic disease‐modifying signals with proven cardiovascular risk reduction. This review synthesizes mechanistic, randomized trial, real‐world, and cardiovascular outcome evidence for GLP‐1RAs in MASLD and metabolic dysfunction‐associated steatohepatitis (MASH). In biopsy‐based trials, liraglutide (LEAN) increased steatohepatitis resolution without fibrosis worsening (39% vs. 9% with placebo), while semaglutide demonstrated dose‐dependent resolution (up to 59% vs. 17% in Phase 2). More recently, semaglutide 2.4 mg weekly met both histologic endpoints at interim analysis in F2–F3 MASH (resolution without fibrosis worsening 62.9% vs. 34.3%; fibrosis improvement ≥ 1 stage 36.8% vs. 22.4%), and tirzepatide (SYNERGY‐NASH) achieved high rates of MASH resolution (44%–62% vs. 10%) with concomitant fibrosis improvement signals (up to 51% vs. 30%). Cardiovascular outcome trials demonstrate consistent reductions in major adverse cardiovascular events with GLP‐1RAs, including liraglutide (LEADER), semaglutide (SUSTAIN‐6 and SELECT), and dulaglutide (REWIND). Mechanistically, GLP‐1RAs reduce hepatic lipogenesis and lipotoxicity, attenuate inflammation, improve insulin sensitivity, and modulate gut–brain–liver signaling, with systemic benefits on weight, blood pressure, and atherogenic lipoproteins. Collectively, the evidence supports GLP‐1RAs, particularly semaglutide and tirzepatide, as foundational therapies for MASLD patients with obesity, type 2 diabetes, advanced fibrosis, or heart failure phenotypes. Key gaps include treatment duration, durability of fibrosis benefit, and effectiveness in cirrhosis, requiring long‐term follow‐up.
- 24 March 2026
- Published by Wiley in Chronic Diseases and Translational Medicine
- Vol. 12 (2) , 85-99
Open AccessGLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes
Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects over 30% of adults worldwide and represents a systemic cardiometabolic disorder in which cardiovascular disease is the leading cause of death. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are uniquely positioned to address this liver–heart axis by combining hepatic disease‐modifying signals with proven cardiovascular risk reduction. This review synthesizes mechanistic, randomized trial, real‐world, and cardiovascular outcome evidence for GLP‐1RAs in MASLD and metabolic dysfunction‐associated steatohepatitis (MASH). In biopsy‐based trials, liraglutide (LEAN) increased steatohepatitis resolution without fibrosis worsening (39% vs. 9% with placebo), while semaglutide demonstrated dose‐dependent resolution (up to 59% vs. 17% in Phase 2). More recently, semaglutide 2.4 mg weekly met both histologic endpoints at interim analysis in F2–F3 MASH (resolution without fibrosis worsening 62.9% vs. 34.3%; fibrosis improvement ≥ 1 stage 36.8% vs. 22.4%), and tirzepatide (SYNERGY‐NASH) achieved high rates of MASH resolution (44%–62% vs. 10%) with concomitant fibrosis improvement signals (up to 51% vs. 30%). Cardiovascular outcome trials demonstrate consistent reductions in major adverse cardiovascular events with GLP‐1RAs, including liraglutide (LEADER), semaglutide (SUSTAIN‐6 and SELECT), and dulaglutide (REWIND). Mechanistically, GLP‐1RAs reduce hepatic lipogenesis and lipotoxicity, attenuate inflammation, improve insulin sensitivity, and modulate gut–brain–liver signaling, with systemic benefits on weight, blood pressure, and atherogenic lipoproteins. Collectively, the evidence supports GLP‐1RAs, particularly semaglutide and tirzepatide, as foundational therapies for MASLD patients with obesity, type 2 diabetes, advanced fibrosis, or heart failure phenotypes. Key gaps include treatment duration, durability of fibrosis benefit, and effectiveness in cirrhosis, requiring long‐term follow‐up.
- Open Access
- 3 February 2026
- Published by MDPI AG in Instruments
- Vol. 10 (1) , 9
The Intelligent Knife (iKnife): Revolutionizing Intraoperative Tissue Diagnosis Through Rapid Evaporative Ionization Mass Spectrometry (REIMS)
The intelligent surgical knife (iKnife), based on rapid evaporative ionization mass spectrometry (REIMS), represents a transformative advance in intraoperative tissue characterization. By integrating mass spectrometry with electrosurgical dissection, the iKnife enables real-time differentiation between cancerous and healthy tissues through molecular fingerprinting of the aerosol generated during cutting. This innovation significantly shortens operative time by eliminating delays associated with conventional histopathological analysis and enhances surgical precision by providing continuous feedback on tissue composition. Since its inception by Zoltán Takáts and colleagues, the iKnife has demonstrated remarkable diagnostic accuracy across multiple cancer types, including breast, ovarian, and colorectal malignancies, with reported sensitivities and specificities > 90% in selected tumour types. Beyond oncology, REIMS technology also shows promise for microbial identification and metabolomic profiling. This review provides a comprehensive overview of the iKnife’s development, underlying principles, clinical validation, and emerging applications, as well as its integration into surgical workflows and the challenges remaining for widespread clinical adoption. Future perspectives include miniaturization, AI-driven spectral interpretation, and expansion into robotic and image-guided surgery.
- 3 February 2026
- Published by MDPI AG in Instruments
- Vol. 10 (1) , 9
Open AccessThe Intelligent Knife (iKnife): Revolutionizing Intraoperative Tissue Diagnosis Through Rapid Evaporative Ionization Mass Spectrometry (REIMS)
The intelligent surgical knife (iKnife), based on rapid evaporative ionization mass spectrometry (REIMS), represents a transformative advance in intraoperative tissue characterization. By integrating mass spectrometry with electrosurgical dissection, the iKnife enables real-time differentiation between cancerous and healthy tissues through molecular fingerprinting of the aerosol generated during cutting. This innovation significantly shortens operative time by eliminating delays associated with conventional histopathological analysis and enhances surgical precision by providing continuous feedback on tissue composition. Since its inception by Zoltán Takáts and colleagues, the iKnife has demonstrated remarkable diagnostic accuracy across multiple cancer types, including breast, ovarian, and colorectal malignancies, with reported sensitivities and specificities > 90% in selected tumour types. Beyond oncology, REIMS technology also shows promise for microbial identification and metabolomic profiling. This review provides a comprehensive overview of the iKnife’s development, underlying principles, clinical validation, and emerging applications, as well as its integration into surgical workflows and the challenges remaining for widespread clinical adoption. Future perspectives include miniaturization, AI-driven spectral interpretation, and expansion into robotic and image-guided surgery.